Skip to main content
Premium Trial:

Request an Annual Quote

Robert Bosch Venture Capital, Peregrine Ventures Join Expanded Variantyx $26M Series C Round

NEW YORK — Robert Bosch Venture Capital (RBVC) said on Monday that it has invested in Variantyx as part of the genomic testing company's expanded $26 million Series C financing round. Peregrine Ventures has also joined the round, according to Variantyx.

In March, Variantyx said it raised $20 million in the Series C round, which was led by GHS Fund (Quark Venture LP and GF Securities) and included new investor IBM Ventures and current investors Pitango Venture Capital, New Era Capital Partners, and 20/20 HealthCare Partners.

Boston-based Variantyx uses a proprietary whole-genome sequencing-based testing method for diagnosing rare inherited and neurological disorders but said earlier this year that it is expanding into oncology and prenatal testing.

As part of the investment from RBVC, the corporate venture capital arm of German engineering firm Bosch Group, Variantyx will team up with Robert-Bosch Hospital to provide clinicians with diagnostic tests and personalized treatment recommendations for cancer patients using its proprietary software.

"Together, Variantyx and Bosch are eyeing to bring new research, diagnostics, and precision medicine to oncology patients and clinicians," Ingo Ramesohl, managing director of RBVC, said in a statement.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.